Why is Suven Life Sciences Ltd falling/rising?

Recent Price Movement and Market Performance

Suven Life Sciences has experienced a notable downtrend in its share price over the past week and month, with losses of 5.44% and 10.50% respectively, significantly underperforming the broader Sensex index, which declined by 1.83% and 1.63% over the same periods. Year-to-date, the stock has dropped 8.30%, compared to a modest 1.58% decline in the Sensex. This recent weakness follows a three-day consecutive fall, during which the stock lost 11.71% of its value. Intraday trading on 12-Jan saw the stock touch a low of ₹152.10, down 4.79%, with heavier volumes concentrated near this lower price point, signalling selling pressure.

Further technical indicators reinforce the bearish sentiment. Suven Life Sciences is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a sustained downtrend. Additionally, investor participation appears to be waning, as delivery volumes on 09 Jan dropped by 26.03% compared to the five-day average, indicating reduced buying interest from market participants.

Long-Term Fundamentals and Financial Health

Despite the recent price decline, Suven Life Sciences has delivered strong returns over longer horizons, with a one-year gain of 18.88%, outperforming the BSE500 index’s 7.51% return. Over three and five years, the stock has surged by 139.44% and 84.00% respectively, well ahead of the Sensex’s 39.89% and 69.39% gains. This suggests that the company has been able to generate significant shareholder value in the past.

However, the company’s underlying financials paint a more concerning picture. Over the last five years, Suven Life Sciences has suffered from poor sales growth, with net sales declining at an annualised rate of 23.11%. Operating profits have deteriorated even more sharply, shrinking by 186.11% annually, indicating persistent operating losses. The company’s ability to service debt is also weak, with an average EBIT to interest ratio of -149.78, signalling that earnings before interest and tax are insufficient to cover interest expenses.

The firm has reported negative results for five consecutive quarters, with the latest quarterly PAT plunging 67.9% to a loss of ₹77.31 crores compared to the previous four-quarter average. Operating cash flow for the year is at a low of ₹-47.39 crores, while cash and cash equivalents at half-year stand at a modest ₹10.79 crores, raising concerns about liquidity and operational sustainability.

Investor Sentiment and Institutional Participation

Interestingly, institutional investors have increased their stake by 0.59% over the previous quarter, now collectively holding 4.56% of the company. This suggests that some sophisticated investors may see potential value or turnaround prospects despite the current challenges. Institutional investors typically have greater resources to analyse company fundamentals, which could provide some support to the stock in the medium term.

Nevertheless, the stock remains risky due to its negative EBITDA and declining profitability. While it has outperformed the market in terms of price appreciation over the past year, profits have fallen by 45.2%, indicating that the rally has not been supported by improving earnings. This disconnect between price and fundamentals may be contributing to the recent sell-off as investors reassess the company’s valuation and growth prospects.

Conclusion: Why the Stock is Falling

The decline in Suven Life Sciences’ share price as of 12-Jan is primarily driven by its weak long-term fundamentals, ongoing operating losses, and deteriorating profitability. Despite strong historical price gains, the company’s negative earnings trend and poor cash flow generation have raised red flags among investors. The recent consecutive days of price falls, underperformance relative to the sector, and technical indicators all point to a cautious market stance. Reduced investor participation and trading volumes near the day’s lows further underscore the selling pressure.

While institutional investors have marginally increased their holdings, the overall risk profile remains elevated due to the company’s inability to generate positive operating cash flows and service debt effectively. This combination of factors explains the current downward momentum in Suven Life Sciences’ stock price, as market participants weigh the challenges ahead against the company’s past market-beating returns.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →